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ABSTRACT
It has long been established that hyperthermia increases the therapeutic benefit of radiation and
chemotherapy in cancer treatment. During the last few years there have been substantial technical
improvements in the sources used to apply and measure heat, which greatly increases enthusiasm for
the clinical use of hyperthermia. These advances are converging with a better understanding of the
physiological and molecular effects of hyperthermia. Therefore, we are now at a juncture where the
parameters that will influence the efficacy of hyperthermia in cancer treatment can be optimised in a
more systematic and rational manner. In addition, the novel insights in hyperthermia’s many biological
effects on tumour cells will ultimately result in new treatment regimes. For example, the molecular
effects of hyperthermia on the essential cellular process of DNA repair suggest novel combination thera-
pies, with DNA damage response targeting drugs that should now be clinically explored. Here, we pro-
vide an overview of recent studies on the various macroscopic and microscopic biological effects of
hyperthermia. We indicate the significance of these effects on current treatments and suggest how
they will help design novel future treatments.
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Introduction
Hyperthermia is an anti-cancer treatment in which tumours
are heated using an exogenous energy source. Heat can dir-
ectly kill cancer cells, but also greatly synergises with radio-
therapy and/or chemotherapy to increase the therapeutic
window [1,2]. Although the effect of heat on the body has
been studied for many decades, if not centuries, ‘modern’
hyperthermia has only been applied in the clinic since the
1980s. Early biological and physical studies revealed that the
various physiological and cellular changes induced by hyper-
thermia are dose dependent [3]. Therefore, heat treatment
can be defined by the temperature that is applied: hyperther-
mia (39–45 C), with temperatures <42 C further defined as
mild temperature hyperthermia, and thermal ablation
(>45 C). A second distinction in hyperthermia treatment is
based on which part of the body is heated. Whole-body
hyperthermia, as the name suggests, subjects the complete
body to increased temperature. In regional hyperthermia an
isolated part of the body, such as a body cavity, limb or
organ, is heated, and during local hyperthermia only the
tumour is heated [4].
To understand how hyperthermia is applied nowadays, it
is essential to realise that this treatment has an extensive his-
tory. Although the modern varieties of hyperthermia applica-
tion can be traced back to the 1960s, elevated temperatures
as a single modality have been employed to treat cancer for
a much longer time, and can even be dated as far back as
5000 BC [5]. In the 18 th and 19 th centuries, hyperthermia
treatment started to be more evidence based. The use of
heat then was based on the observation that tumours from
patients started to shrink when the patients suffered from
febrile diseases such as malaria or erysipelas. As a result, the
surgeon Fehleisen started to infect cancer patients with bac-
teria, thus causing erysipelas, with the aim of eliminating
tumours. Around 1900, William B. Coley developed special
toxins, Coley’s toxins, to achieve the same effect, and he per-
formed many studies on its effectiveness [6]. The following
years were extremely important for the modern use of hyper-
thermia. It was the period in which exogenous sources such
as heated water baths started to be used to increase the tem-
perature of gynaecological tumours [7]. Moreover, radiother-
apy was introduced around the same time, and when
clinicians and researchers started combining it with heat, they
found that hyperthermia increased sensitivity to radiation in
tumours [8]. This breakthrough stimulated an increase in the
number of both clinical and fundamental studies from
the 1950s until the present day. To this day, mild hyperther-
mia is used as a sensitiser for radiotherapy, but also for
chemotherapy.
Initially, research on hyperthermia revolved around finding
an optimal treatment temperature and time, or in short, an
optimal thermal dose. These translational studies focused on
creating a therapeutic window with maximum benefits of
hyperthermia with minimal side effects. However, those early
studies assumed that hyperthermia was only effective if it
would directly kill cells, which only occurred when
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temperatures exceeded at least 42 C. This made hyperther-
mia less feasible and thus less attractive in a clinical setting,
causing a dampened enthusiasm for the treatment [9]. As a
result, there was a strong demand to improve hyperthermia
technology, and a second line of hyperthermia research,
focused on the physics of heating, quickly emerged. As of
now, this field of research continues to improve not only the
hyperthermia application techniques, but also the method of
locally depositing heat and measuring it in the patient [10].
The measuring tools aid clinicians in treating their patients
optimally and it helps them document treatment outcomes
for clinical research. Another line of hyperthermia research
that has raised enthusiasm for cancer treatment employing
heat has a biological and fundamental nature. Biological
research strives to understand the biological mechanisms of
hyperthermia at every temperature. Although this type of
research may not always be directly applicable to clinical
treatment per se, it will ultimately result in revolutions in the
way we use hyperthermia in the clinic, by exploitation of the
many cellular and physiological effects that hyperthermia has
in tumours (Figure 1) [5].
This review aims to illustrate the importance of biological
research to mild hyperthermia, since hyperthermia in this
temperature range is the most prominent in the clinic. To
demonstrate the broad potential of heating tumours, we pre-
sent an overview of the biological effects of mild hyperther-
mia and describe their relevance in current treatment
regimes. Moreover, we will describe how the biological
research continues to influence the way we think about
hyperthermia by presenting examples of treatment
innovations that are not, or not yet, clinically applied, but
exploit one or more biological effects of heat.
Macroscopic effects of hyperthermia
When a tumour is heated, a number of physiological changes
occur. One of the earliest recognised physiological changes
induced by hyperthermia is its effect on the vascular system.
Hyperthermia causes an increase in blood flow in the heated
area, and by expanding the vessels the heat improves their
permeability (Figure 1A) [11–13]. Most of the physiological
changes upon hyperthermia treatment are secondary to
effects on tumour blood flow [14]. In fact, blood flow is one
of the predominant factors governing tumour response to
heating [15,16]. It is a potent cooling mechanism which thus
influences the delivery of heat to a tissue. Blood flow in
tumours is also a principal factor responsible for the micro-
environmental conditions within tumours, and since cells
under oxygen-deprived and highly acidic conditions are more
responsive to the effects of heat [17,18], blood flow will play
a major role in influencing the cellular heat response, and
subsequently that of the tumour.
How quickly the macroscopic changes of hyperthermia are
seen and their degree of change generally depends on the
time and temperature of heating. As soon as heat is applied
to a tumour the blood flow increases, but these effects are
cancelled upon treatment with temperatures that surpass
44.5 C [11,19–25]. However, the degree of increase and how
long it is maintained is very heterogeneous depending on
both the temperature applied and the tumour model used
Figure 1. Biological effects of local hyperthermia in the tumour. A tumour, represented by the pictogram in the centre, and the diverse physiological and molecular
effects of heat are indicated. (A) Hyperthermia alters physiology of the centrally located tumour by affecting its vasculature: heat increases the blood flow and vessel
permeability. (B) Heat causes proteins to unfold and increases the intracellular amount of protein-chaperoning heat-shock proteins. (C) Temperatures exceeding 37 C
result in increased cell membrane fluidity, thereby influencing their permeability. Specific biological effects of heat on membranes may be further affected by altering
properties of membrane-bound-proteins. (D) Local heat helps to activate the immune system and causes it to attack the tumour directly, but might also cause a sys-
temic effect by which immune cells attack tumour cells distant from the heated tumour. (E) Hyperthermia affects DNA damage repair pathways by deactivating spe-
cific repair proteins.
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[11,26]. The primitive construction and poor organisation of
tumour vessels results in them being more permeable than
normal tissue vessels [27]. As flow increases in response to
heat, fluid will begin to leak out of the vessels into the extra-
cellular space [25]. This oedema will eventually increase inter-
stitial fluid pressure which subsequently causes vascular
compression and a decrease in perfusion. This could explain
the observations that vascular perfusion starts to decrease
after about 30min of heating the tumour to 42.5 C and
above [19,23–25]. However, it should be noted that at least
one study found that this did not occur until a temperature
of 44.5 C was achieved [22]. In addition, temperatures
beyond 44.5 C will directly kill endothelial cells, and this will
cause vascular damage, resulting in haemorrhage that accen-
tuates the already decreased perfusion [11,28]. In some exam-
ples the inherent vascular damage in the tumour can be so
severe that a total vascular shut down occurs, even at tem-
peratures as low as 42.5 C [25]. After heating, flow typically
returns to normal at lower temperatures, but continues to
decrease in those tumours where vascular damage was
already initiated [19,22,24,25].
As mentioned above, the tumour vasculature is structurally
and functionally abnormal and thus fails to meet the
demands of the growing tumour mass, which is why tumours
are characterised by regions of oxygen and nutrient depriv-
ation, high lactate levels and extracellular acidosis [27,29].
Heat-induced vascular changes will further modify the micro-
environmental parameters, although the mechanism is also
dependent on the applied temperature. High temperatures
cause vascular collapse which will further reduce oxygen and
nutrient delivery to tumour cells. This is reflected by an escal-
ation in energy deprivation [30], lactic acid accumulation [31],
acidity [30], and hypoxia [32,33]. For lower temperatures the
increase in perfusion is associated with an increased oxygen
delivery [32,34–37], but this greater availability of oxygen
leads to an increased consumption of oxygen [14,38,39]. Even
though an enhanced oxygen consumption could be expected
to decrease the diffusion distance of oxygen and thus elevate
the level of tumour hypoxia, this has not been shown.
Although the macroscopic effects of hyperthermia can be
classified as well-studied, there is controversy about the
improvement in oxygenation to how long those effects last.
Some studies have shown that this improvement can last for
up to 24 h after heating at mild temperatures [34,36], and this
has been suggested as one of the reasons why hyperthermia
enhances radiation administered clinically in a fractionated
schedule [40]. However, this prolonged improvement in
tumour oxygenation is difficult to explain, because the
physiological changes that are likely to account for improved
oxygenation with mild heat treatments are unlikely to be
maintained after the blood flow increase has ceased. More
consistent with those physiological effects, other studies have
shown that tumour oxygenation actually rapidly returns to
normal when the heating at mild temperatures ceases [35].
Nonetheless, the several macroscopic effects of hyperthermia
have established a central position in its modern use.
Moreover, the transient increase in blood flow and resulting
vascular leakage forms the basis for generating methods to
increase drug delivery to a place of interest, for example, via
the application of thermosensitive liposomes [41–44].
The heat shock response
Heat activates a cellular mechanism that defends against pro-
tein stress. This heat shock response consists of a rapid pro-
duction of heat shock proteins (HSPs), a specific group of
proteins that chaperone denatured proteins and thereby pre-
vent formation of toxic protein aggregates (Figure 1B)
[45–47]. This defence mechanism is not limited to the
response to heat, but is also activated by several other forms
of stress, such as hypoxia and infection, and is therefore of
vital importance for life [47]. However, when it comes to
treating cancers with mild hyperthermia, the heat shock
response has an undesirable side effect: it causes tumours to
become thermotolerant. Thermotolerance is a phenomenon
that can be described as insensitivity to heat treatments
within 48–72 h after the initial treatment. It has a pivotal role
in the hyperthermia field because it demonstrates the import-
ance of properly scheduling hyperthermia sessions for
patients.
HSPs have been recognised to play a role in the develop-
ment of thermotolerance for a long time, because they are
thought to protect tumour cells from protein denaturation
induced by hyperthermia [48–51]. Moreover, tumours some-
times have a constitutively high level of HSPs that protect
them from innately higher levels of protein stress, causing
the tumours to be fully dependent on these high levels.
Therefore, specific HSP inhibitors have been developed and
have found their way into the clinic [52]. Because of their
availability and clinical use, employing these types of drugs
together with hyperthermia should be considered in order to
increase the effective therapeutic window and prevent ther-
motolerance. Although the detailed effects on thermotoler-
ance are still rather unclear, the combination of heat and HSP
inhibitors does increase cell sensitivity towards hyperthermia
[53]. It has also been proposed that activation of the heat
shock response is inhibited by acute acidification, and indeed,
sensitivity of cells towards heat is increased when it is com-
bined with drugs that lower the pH in the cell, such as lonid-
amine, especially when cells were slightly acidic already [54].
However, as will be described below, HSPs also occupy an
important role in cancer immunology and in that context
their role is actually thought to be beneficial for the patient.
Therefore it will be essential to thoroughly investigate the
implications of combining different variants of HSP inhibitors
with hyperthermia on treatment efficacy, thermotolerance,
and immunological effects, before applying them in a clinical
setting.
Cellular membrane and drug uptake
One of the ways hyperthermia contributes to sensitising cells
towards chemotherapeutics, is by increasing fluidity of the
cytoplasmic membrane (Figure 1C). The cytoplasmic mem-
brane consists of a phospholipid bilayer and proteins, and it
forms the outer layer of the cell. Interactions between
448 N. VAN DEN TEMPEL ET AL.
D
ow
nl
oa
de
d 
by
 [E
ras
mu
s U
niv
ers
ity
] a
t 0
0:1
3 0
3 N
ov
em
be
r 2
01
7 
proteins and lipids in the membrane cause it to respond to
temperature changes in a very dynamic fashion [55].
Regulation of the membrane fluidity is essential for homeo-
stasis and therefore conserved in many species. It is clear that
the membrane plays a considerable role in the stress
response, including the response to heat-shock [56–58].
Membrane stress triggers various signalling cascades which
transduce their signal to the heat shock transcription factor
HSF1, which ultimately increases expression of the HSPs
[58,59].
When the membrane becomes more fluid due to heat, its
physical permeability for some compounds will increase [60].
This is probably one of the reasons why some chemothera-
peutics will be able to pass the cell barrier more effectively
when the cells are treated with hyperthermia. For example,
several reports show that the concentration of the chemo-
therapeutic cisplatin increases in the cell when it is treated
with hyperthermia [61–63]. Moreover, heat also contributes to
structural changes in the membrane by altering the behav-
iour of membrane-embedded proteins, and this will also
increase cellular cisplatin concentrations; this is illustrated by
heat facilitating multimerisation of a copper transporter
(CTR1) that is responsible for cisplatin uptake [64]. Knowledge
about the altered behaviour of the cell membrane in condi-
tions of hyperthermia has mainly been used in regional
hyperthermia treatment, where a heated chemotherapeutic is
flushed on a specific part of the body such as the peritoneum
(HIPEC) or the bladder (HIVEC) [43,65]. However, the tempera-
ture-mediated effects on the cell membrane will also play
a role with the implementation of thermosensitive
liposomes [42].
The effects of hyperthermia on the membrane might be
counteracted by an evolutionary conserved adaptation
response. The exact mechanism by which cells compensate
their membrane fluidity to heat is not known, but recent
studies have revealed that the acyl-CoA dehydrogenase
down-regulates a lipid desaturase upon heat in the model
system Caenorhabditis elegans. This effectively creates a more
rigid membrane structure that compensates for the increased
fluidity [66,67]. Such an adaptive response might be relevant
for the development of thermotolerance, thus it will be of
importance to elucidate whether this mechanism also occurs
in human cells after hyperthermia. In this context, it is import-
ant to realise that the composition of the membrane as well
as its reaction to environmental changes can be deregulated
in tumours, since this might have consequences for the treat-
ment regime [68]. Ultimately, research done on the subject
will deliver new strategies to either mimic or enhance the
effects of hyperthermia on the membrane, or to prevent
unwanted side effects.
The immune system and hyperthermia
Fever and hyperthermia are both characterised by increased
temperatures, and both contribute to the activation of the
immune system (Figure 1D) [69,70]. Treatments of cancer
patients by using hyperthermia and stimulating their immune
system have always been closely intertwined, as can be
exemplified by the fact that William B. Coley is regarded as
one of the fathers in the hyperthermia field, but is also seen
as one of the pioneers in immunotherapy [6,69]. The many
intriguing ways in which hyperthermia stimulates the immune
system has great impact on the rationale of hyperthermia
treatment in oncology, as is clear from the many reviews on
the subject [5,69–73]. Currently, it is thought that there are
two closely related ways in which local hyperthermia can
modulate the immune system [5]. The first effect of hyper-
thermia on immunity is localised to the heated tumour, but,
secondly, local hyperthermia can also stimulate a systemic
antitumour reaction that can strike tumour cells that are dis-
tant from the heated tumour [69,70].
Increased temperatures affect both adaptive and innate
immunity [70,73]. The way temperature regulates the immune
system is not only dependent on the magnitude of the tem-
perature increase that is applied or achieved, but also on the
duration [70,72,74]. However, some effects occur quickly and
are therefore relevant in hyperthermia treatment. The
increased blood flow resulting from mild heating of the
tumour can promote attraction of immune cells via improving
trafficking between the tumour and the draining lymph
nodes [69]. It has also been shown that heat causes changes
in adhesion molecules of the tumour vasculature. Specifically,
the expression of the glycoprotein intracellular adhesion mol-
ecule 1 (ICAM-1) is increased via heat-induced increased inter-
leukin 6 (IL-6) signalling. ICAM-1 then attracts effector/
memory T-cells [69,75,76]. Hyperthermia not only alters
expression of vascular adhesion molecules, but also induces
an increased expression of surface molecules on tumour cells.
At 39 C, heat increases the MHC class I polypeptide-related
sequence A (MICA), a molecule which increases cell sensitivity
to natural killer cells [69,77]. At a temperature of 43 C, heat
will increase the level of MHC class I molecules, which attract
cytotoxic T-cells [69,78]. Febrile temperatures also enhance
functions of dendritic cells, and their enhanced antigen-pre-
senting function increases stimulation of T-cells [70,79–81]. It
is thought that the heat-mediated increase in membrane flu-
idity has effects on organising the response of the adaptive
immune system, promoting activation of T-cells in areas
where the temperature is increased [82–84].
The most interesting connection between immunity and
the heat-shock response is the function of the increased
HSPs, especially that of Hsp70. Like other HSPs, Hsp70 is pro-
duced upon heat treatment, but it can be released from cells.
In the extracellular environment, Hsp70 will bind various
immune cell surface receptors, which will in turn release vari-
ous pro-inflammatory molecules. In this environment, Hsp70
stimulates dendritic cells and macrophages by acting as a
damage-associated molecular pattern (DAMP) [70]. Moreover,
Hsp70s can stimulate the adaptive immune system by trans-
ferring chaperoned tumour proteins to antigen-presenting
cells, which evokes a tumour-specific T-cell response
[69,85–87]. This T-cell response presumably has the ability to
target all tumour cells, including metastases [88].
Although the role of hyperthermia in immunity has revolu-
tionised the rationale behind using hyperthermia in oncology
treatment, the connection has only recently gained more
interest with the acknowledgement of the role for
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immunotherapy in oncology [89]. To exploit the effects of
hyperthermia on the immune system in the future, it will be
especially important to fully understand the temperature
dynamics and corresponding effects of the HSPs, since their
role provokes the most tumour-specific immune response
[90,91]. This is illustrated by the finding that Hsp70 can be
used as an anti-cancer vaccine to mimic and maximise the
response of hyperthermia [92,93].
Hyperthermia and DNA repair
It has long been known that hyperthermia increases cancer
cell sensitivity for agents that cause DNA damage or interfere
with DNA metabolism. One of the earliest discoveries and
well-studied examples of an agent that causes DNA damage,
and synergises with heat, is ionising radiation [94]. However,
heat also increases the degree of cell killing caused by certain
types of chemotherapy, such as cisplatin and alkylating
agents [95]. The mechanism by which hyperthermia sensitises
to DNA damaging agents has been extensively studied, but
the results are often difficult to interpret because of the use
of different temperatures and an overlap in the several DNA
damage repair pathways. The many hypotheses that consider
what effects hyperthermia has on DNA have recently been
reviewed [96].
Many researchers have tried to elucidate the mode of
action of hyperthermia on DNA. Some early reports indicated
that hyperthermia directly caused DNA damage and claimed
that there were more chromosomal aberrations and DNA
breaks after hyperthermia treatment [97,98]. Moreover, heat-
ing cells to 41.5 C increased the amount of phosphorylation
of histone H2AX (cH2AX), which is considered a marker for
DNA double strand breaks [99]. However, there is also a large
body of literature that describes hyperthermia as having no
direct damaging effect on DNA, but rather interferes with the
activity of proteins important for repairing DNA caused by an
exogenous agent, such as radiotherapy (Figure 1E) [96].
Identifying specific DNA repair pathways that are targeted
by hyperthermia is not straightforward. This task has been
attempted by employing a genetic approach, in which the
sensitivity towards the combination of exogenously applied
DNA damage and heat in wild-type cells is compared to cells
that are deficient for a specific repair pathway. If hyperther-
mia results in inactivation of a repair pathway required for
the repair of the induced DNA lesions, then heated wild-type
cells will be more sensitive towards the DNA damaging agent
than cells that are not heated. In the scenario that the repair
deficient cell line is deficient for a pathway that is targeted
by hyperthermia, then the cells will not be further sensitised
by the applied heat. However, the spectrum of different
lesions induced by a single DNA damaging agent, as well as
the possibility that hyperthermia targets multiple DNA repair
pathways, prevents conclusive interpretation of data obtained
using this genetic approach. Indeed, multiple DNA repair
pathways, such as base excision repair [66] for single strand
DNA lesions and non-homologous end joining for double
strand breaks [100], are believed to be inhibited by hyper-
thermia [96]. However, the results obtained in these studies
are often based on experiments done with temperatures
above 43 C, so it remains unclear whether inhibition of these
DNA repair pathways add to the effects of mild hyperthermia.
There is therefore still significant experimental ground to be
covered before the mystery of how mild hyperthermia influ-
ences DNA metabolism is solved.
Nonetheless, when we can identify the effects of hyper-
thermia on DNA in cancer cells, the information obtained can
help the hyperthermia field with questions such as how to
minimise side effects and toxicity to healthy tissues, and how
to maximise DNA damage load in the tumour. For example, it
was discovered that hyperthermia functionally inhibits the
DNA repair pathway of homologous recombination [101,102].
This repair pathway acts in the S-phase and G2-phase of the
cell cycle to faithfully restore double strand breaks by using
an intact copy of broken DNA as a template for repair. When
such a double strand break occurs, it triggers a cascade that
results in nucleolytic processing of the double strand DNA
ends into single strand DNA, which is subsequently coated by
the single-strand binding protein RPA. This is then replaced
by RAD51 with the help of BRCA2. This RAD51 recombinase
protein is believed to be of vital importance for the subse-
quent search for homologous DNA and the invading of this
DNA, and is therefore regarded as the most essential compo-
nent in homologous recombination. After the missing DNA is
restored based on the sequence information of its identical
sister chromatid in the cell, the intertwined DNA structure is
resolved leaving two whole DNA molecules [103,104]. In the
aforementioned study, it was shown that hyperthermia
(>40 C) inhibits the accumulation of the RAD51 at sites of
DNA damage via targeting the BRCA2 protein for proteasomal
degradation [101].
Homologous recombination is involved in repair of breaks
caused by radiation treatment, and therefore the finding that
hyperthermia inhibits this DNA repair pathway provides at
least part of the explanation for hyperthermia’s sensitising
potential towards ionising radiation. However, homologous
recombination is not only responsible for repairing double
strand breaks that result from exogenous sources, but also
acts to repair breaks that result from collapsing of replication
forks. The finding that hyperthermia inhibits homologous
recombination is therefore of particular interest, because it
opens up new possibilities of treatments that can be com-
bined with hyperthermia, such as PARP-1 inhibitors [105].
PARP-1 inhibitors are a relatively new class of chemotherapy
which cause collapse of replication forks [106]. These PARP-1
inhibitors gained clinical interest because they specifically kill
cells that are deficient in homologous recombination, while
showing little toxicity to normal cells [106,107]. Thus, PARP-1
inhibitors are a prime example of a precision treatment for
tumours of BRCA1/2 mutation carriers, as the tumour cells of
these patients, but not their normal cells, are homologous
recombination deficient. The demonstration that mild heat
phenocopies BRCA deficiency and induces homologous
recombination deficiency provides a rational for extending
PARP-1 inhibitor treatment outside of the limited group of
BRCA mutation carriers. Clinical trials should now be consid-
ered in which PARP-1 inhibitors are combined with hyperther-
mia to locally induce homologous recombination deficiency
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in tumours. This combination may have minimal side effects,
because both treatments, which have little toxicity on their
own, will only need to be applied temporarily. Therefore, we
predict that it will only be a matter of time before this com-
bination therapy will be applied in a clinical setting.
The future of hyperthermia
Hyperthermia has been used in the clinic for decades, and
clinical studies have clearly demonstrated that heating
tumours has benefit when added to radiation or to chemo-
therapy [5,108–110]. Moreover, hyperthermia is now readily
available to treat a broad range of tumours, similar to radio-
therapy and broad-spectrum chemotherapy, but unlike the
latter two, hyperthermia has no severe side effects [10,111].
These beneficial features of hyperthermia together with the
physiological and molecular effects that we have summarised
in this review (Figure 1), illustrate the potential of hyperther-
mia treatment in oncology.
The impact of hyperthermia in cancer treatment will only
increase in the future, as we learn how to more effectively
exploit the multiple biological effects of the heat on the
tumour. However, the time has already arrived to translate
the biological findings about hyperthermia into benefits for
cancer patients. The importance of thermal dose has always
been recognised in the context of hyperthermia treatment,
and finding the optimal thermal dose for each biological
effect will result in insights that will enhance the efficacy of
the heat, and eventually in one or more doses that fit the
treatment regimen envisioned by the practitioner. The possi-
bilities to optimise hyperthermia treatment are greatly aided
by the current advantages in the application techniques for
hyperthermia: the heating systems have not only become
more specialised and effective in heating, but it is now also
possible to measure real-time heat deposition by MRI [5].
Although hyperthermia itself is advancing beyond previous
possibilities, the collection of possible synergising agents are
also emerging. With the expanding interest in the use of pro-
ton therapy in oncology, it has been suggested that cells har-
bouring defects in homologous recombination are more
sensitive towards proton irradiation than to photon irradiation
[112,113]. Since, as we explained above, heat causes a defect
in homologous recombination, there is a rational basis for the
combination of hyperthermia with proton therapy. Ultimately,
the collective efforts of clinicians, physicists and biologists will
result in an effective, versatile and evidence-based use of
hyperthermia in oncology that is bound to gain more popu-
larity in the future.
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